VRITEL TRIO 6.25 TABLET
Generic Salt Composition: Telmisartan 40mg + Cilnidipine 10mg + Chlorthalidone 6.25mg
Price: ₹48 MRP: ₹165
Save up to 71% compared to branded medicines.
Top Brand Substitutes & Equivalents
Telma-CT, Cila-CT, Telmisartan+Cilnidipine+Chlorthalidone, Telsartan-CT, Cilacar-T, Chlorthalidone+Telmisartan+Cilnidipine, Telmi-CT, Cilin-T, Telmika-CT, Telvas-CT, Telma-Trio, Cilnidipine-Telmisartan-Chlorthalidone, Telmisartan-Cilnidipine-Chlorthalidone, Telsar-CT, Telmichek-CT, Telmivox-CT, Telmifast-CT, Telmigen-CT, Telmizest-CT, Telmimax-CT, Telma 40, Telmikind 40, Tazloc 40, Telpres 40, Micardis 40, Telvas 40, Cresar 40, Telista 40, Arbitel 40, Inditel 40
Product Overview & Uses
VRITEL TRIO 6.25 TABLET is a sophisticated, triple-action formulation designed for the effective management of essential hypertension. As a key product in the Blood Pressure & Heart category, it combines Telmisartan, an angiotensin II receptor blocker, with Cilnidipine, a calcium channel blocker, and Chlorthalidone, a thiazide-like diuretic. This combination is specifically engineered for patients who require multi-modal therapy to achieve target blood pressure goals. By blocking the action of vasoconstrictor hormones, inhibiting calcium influx into vascular smooth muscle, and promoting the excretion of sodium and water, VRITEL TRIO 6.25 TABLET offers a robust approach to cardiovascular health. Regular use of VRITEL TRIO 6.25 TABLET helps in preventing long-term complications associated with uncontrolled hypertension, such as stroke, myocardial infarction, and renal impairment. It is essential to follow the prescribed dosage of VRITEL TRIO 6.25 TABLET under medical supervision to ensure optimal therapeutic outcomes and safety.